Prolonged dexamethasone cuts delayed nausea after chemo

August 22, 2012
Prolonged dexamethasone cuts delayed nausea after chemo
Adding dexamethasone to prochlorperazine on days two and three, following palonosetron and dexamethasone on day one, reduces delayed nausea in patients receiving chemotherapy containing a platinum-based drug or an anthracycline, according to research published online Aug. 20 in the Journal of Clinical Oncology.

(HealthDay) -- Adding dexamethasone to prochlorperazine on days two and three, following palonosetron and dexamethasone on day one, reduces delayed nausea (DN) in patients receiving chemotherapy containing a platinum-based drug or an anthracycline, according to research published online Aug. 20 in the Journal of Clinical Oncology.

Joseph A. Roscoe, Ph.D., of the University of Rochester in New York, and colleagues conducted a randomized, double-blind study of the effectiveness of several for the prevention of DN: palonosetron plus dexamethasone followed by prochlorperazine; granisetron plus dexamethasone followed by prochlorperazine; aprepitant plus palonosetron plus dexamethasone followed by aprepitant plus dexamethasone; or palonosetron plus dexamethasone followed by prochlorperazine plus dexamethasone.

The researchers observed no difference between the effects of palonosetron and granisetron on DN when given with dexamethasone on day one followed by prochlorperazine on days two and three. Also, aprepitant was no more effective at reducing DN than prochlorperazine. Some benefit was achieved, however, by adding dexamethasone to prochlorperazine on days two and three.

"Over half of the patients studied experienced DN, and control afforded by all of the antiemetic regimens examined was inadequate. The finding that a second-generation 5-hydroxytryptamine (5-HT RA), palonosetron, showed no greater efficacy in controlling DN than a first-generation 5-HT RA was disappointing," the authors write. "We were similarly disappointed that aprepitant provided no significant benefit over prochlorperazine in controlling DN. More effective regimens for controlling DN are needed and should include the addition of prolonged dexamethasone."

Two authors disclosed to the pharmaceutical industry.

Explore further: Chemo-induced nausea remains big problem, study says

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Chemo-induced nausea remains big problem, study says

June 2, 2011
A large, phase III study of four commonly used drug regimens to treat chemotherapy-induced nausea concluded that while two regimens were better at managing patients’ queasiness, none were totally effective – prompting ...

Chemo combination promising for multiple myeloma

May 2, 2012
(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...

Recommended for you

Bolstering fat cells offers potential new leukemia treatment

October 16, 2017
Killing cancer cells indirectly by powering up fat cells in the bone marrow could help acute myeloid leukemia patients, according to a new study from McMaster University.

Study reveals complex biology, gender differences, in kidney cancer

October 13, 2017
A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation.

Cholesterol byproduct hijacks immune cells, lets breast cancer spread

October 12, 2017
High cholesterol levels have been associated with breast cancer spreading to other sites in the body, but doctors and researchers don't know the cause for the link. A new study by University of Illinois researchers found ...

New drug hope for rare bone cancer patients

October 12, 2017
Patients with a rare bone cancer of the skull and spine - chordoma - could be helped by existing drugs, suggest scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute and the Royal ...

Scientists pinpoint surprising origin of melanoma

October 12, 2017
Led by Jean-Christophe Marine (VIB-KU Leuven), a team of researchers has tracked down the cellular origin of cutaneous melanoma, the deadliest form of skin cancer. The team was surprised to observe that these very aggressive ...

Team finds a potentially better way to treat liver cancer

October 12, 2017
A Keck School of Medicine of USC research team has identified how cancer stem cells survive. This finding may one day lead to new therapies for liver cancer, one of the few cancers in the United States with an incidence rate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.